ReviewFrontiers in oncology2015
Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity.
Review in Frontiers in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Beneficial Probiotics with New Cancer Therapies for Improved Treatment of Hepatocellular Carcinoma.Diseases (Basel, Switzerland) · 2025Review
- Microneedle System Coated with Hydrogels Containing Protoporphyrin IX for Potential Application in Pharmaceutical Technology.Methods and protocols · 2024Article
- Lutetium Texaphyrin-Celecoxib Conjugate as a Potential Immuno-Photodynamic Therapy Agent.Journal of the American Chemical Society · 2024Article
- Photodynamic Therapy and Adaptive Immunity Induced by Reactive Oxygen Species: Recent Reports.Cancers · 2024Review
- Pharmaceutical Approach to Develop Novel Photosensitizer Nanoformulation: An Example of Design and Characterization Rationale of Chlorophyll α Derivative.Pharmaceutics · 2024Article
- The use of RNA-based treatments in the field of cancer immunotherapy.Molecular cancer · 2023Review
- Photodynamic Therapy-Mediated Immune Responses in Three-Dimensional Tumor Models.International journal of molecular sciences · 2021Review
- ROS Pleiotropy in Melanoma and Local Therapy with Physical Modalities.Oxidative medicine and cellular longevity · 2021Review
- Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy.Cancer immunology, immunotherapy : CII · 2020Article
- Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma.Frontiers in oncology · 2020Review
- The Course of Immune Stimulation by Photodynamic Therapy: Bridging Fundamentals of Photochemically Induced Immunogenic Cell Death to the Enrichment of T-Cell Repertoire.Photochemistry and photobiology · 2019Review
- Mechanisms of immunogenicity in colorectal cancer.The British journal of surgery · 2019Review
- A NIR-responsive indocyanine green-genistein nanoformulation to control the polycomb epigenetic machinery for the efficient combinatorial photo/chemotherapy of glioblastoma.Nanoscale advances · 2019Article
- Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B.Hepatology (Baltimore, Md.) · 2017Review
- The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development.Oncoimmunology · 2016Review
- Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions.Annals of the American Thoracic Society · 2016Review
- Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Seminars in immunology · 2016Review
- Targeting Antitumor Immune Response for Enhancing the Efficacy of Photodynamic Therapy of Cancer: Recent Advances and Future Perspectives.Oxidative medicine and cellular longevityReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy (PDT) of cancer is an approved therapeutic procedure that generates oxidative stress leading to cell death of tumor and stromal cells. Cell death resulting from oxidative damage to intracellular components leads to the release of damage-associated molecular patterns (DAMPs) that trigger robust inflammatory response and creates local conditions for effective sampling of tumor-associated antigens (TAA) by antigen-presenting cells. The latter can trigger development of TAA-specific adaptive immune response. However, due to a number of mechanisms, including epigenetic regulation of TAA expression, tumor cells evade immune recognition. Therefore, numerous approaches are being developed to combine PDT with immunotherapies to allow development of systemic immunity. In this review, we describe immunoregulatory mechanisms of epigenetic treatments that were shown to restore the expression of epigenetically silenced or down-regulated major histocompatibility complex molecules as well as TAA. We also discuss the results of our recent studies showing that epigenetic treatments based on administration of methyltransferase inhibitors in combination with PDT can release effective mechanisms leading to development of antitumor immunity and potentiated antitumor effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.